- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Top 5 Articles of the Week: February 2-7
Author(s):
Key Takeaways
- Allergan Aesthetics' AA Signature program offers personalized treatments using its diverse product portfolio, including Botox Cosmetic and CoolSculpting.
- EltaMD's new SPF 50 sunscreen, available in untinted and color-correcting versions, is clinically proven to repair and protect post-procedure skin.
Explore the top headlines of the week including Allergan Aesthetics' new AA Signature program, the launch of EltaMD's new UV Skin Recovery broad spectrum SPF 50 face sunscreens, and more.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
1. ICYMI: Allergan Unveils AA Signature Program for Personalized Treatment
Allergan Aesthetics, an AbbVie company, has launched its new AA Signature program. The multimodal program will provide a unique and innovative approach to treatment using Allergan’s extensive product portfolio, which includes facial injectables like Botox Cosmetic and body contouring procedures such as CoolSculpting.
2. EltaMD Unveils Breakthrough Post-Procedure Sunscreen Clinically Proven to Repair and Protect Skin
EltaMD Skincare, the #1 dermatologist recommended professional sunscreen brand, announced the launch of its new UV Skin Recovery broad spectrum SPF 50 face sunscreens, including an untinted version and a red color correcting version with a green tint. Joel Cohen, MD, FAAD, FACMS, and Lia Arvanitidou, PhD, shared insights into the science behind this innovative sunscreen and its clinical efficacy.
3. Pilot Study Finds Intradermal Botulinum Toxin A Safe and Effective for Melasma
A pilot study found intradermal botulinum toxin A to be safe and effective for melasma treatment. A randomized trial and in vitro study confirmed that the clinical depigmenting benefits do not harm the skin cells or pose any risk for patients.
4. Phase 3b Data Reinforce Rapid, Long-Lasting Efficacy of RelabotulinumtoxinA for Glabellar Lines
Galderma recently presented the latest findings from its phase 3b RELAX clinical trial at the International Master Course on Aging Science in Paris, France. The results reaffirm the robust efficacy, rapid onset, and extended duration of aesthetic improvements achieved with a single treatment of RelabotulinumtoxinA (Relfydess) for moderate to severe glabellar lines.
5. Combining Minoxidil and LLLT Does Not Improve Treatment Outcomes for Androgenic Alopecia
A recent systemic review and meta-analysis compared minoxidil alone to minoxidil and low-level laser therapy for the treatment of androgenic alopecia. It was found that LLLT, which uses wavelengths of red or near-infrared light, does not increase the effectiveness of minoxidil treatment.
